R
RAPT Therapeutics
Develops clinical-stage therapies targeting inflammatory and immunological diseases through small-molecule and biologic drug research
About RAPT Therapeutics
RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative oral therapeutics aimed at targeting key drivers of the immune system. The company's mission is to transform the treatment of cancer and inflammatory diseases through cutting-edge science. RAPT Therapeutics primarily serves patients suffering from cancer and inflammatory conditions, offering them new hope through advanced medical treatments. Operating in the biopharmaceutical market, the company leverages its expertise in immunology to create therapies that intelligently target specific pathways within the immune system.
The business model of RAPT Therapeutics revolves around research and development (R&D) of novel drug candidates, which are then advanced through clinical trials. The company generates revenue through partnerships, licensing agreements, and potential future sales of its proprietary drugs once they receive regulatory approval. RAPT Therapeutics also attracts investment opportunities, which help fund its ongoing R&D efforts and clinical trials.
Key clients include healthcare providers, research institutions, and pharmaceutical companies interested in innovative treatments for cancer and inflammatory diseases. The company aims to improve and empower countless lives by offering effective and targeted therapeutic solutions.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2019
Open roles
RAPT Therapeutics in the San Francisco ecosystem
The RAPT Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Kleiner Perkins
The Column Group
Source: Dealroom Talent Intelligence.
Patents
19 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See RAPT Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
GSK acquires RAPT (March 2026)
